European Companies Search Engine
EU funding (€7,285,044): Comparative signature of Marburg virus cell activation as a blueprint for the identification of antiviral targets against newly emerging viruses Hor15 Nov 2024 EU Research and Innovation programme "Horizon"
Overview
Text
Comparative signature of Marburg virus cell activation as a blueprint for the identification of antiviral targets against newly emerging viruses
Identifying cellular attachment factors and functional receptors plays a critical part in developing an understanding of a newly emerging virus. However, the identification and therapeutic targeting of plasma membrane proteins critical for virus infection is often difficult due to the transient nature of virus-cell binding and the overall kinetics of the infection process. Our goal is to interrogate virus-host cell interaction and cellular uptake of Marburg virus (MARV), a highly pathogenic and clinically relevant member of the filovirus family. To specifically target virus-plasma membrane interaction we will use a unifying inverted infection platform that allows us to halt and synchronize virus infection at the cell binding stage. Our approach is compatible with BSL-4 environment and multi-Omics technologies. It will allow us to identify the signature of virus-host cell activation, i.e., proteins involved in virus-cell entry in a tissue-specific manner. This screen will be complemented by an innovative combination of proteomics, virus-host cell interaction analysis and imaging approaches to pinpoint and characterize the involved cellular and viral proteins, their post-translational modifications and how they mechanistically concert in viral uptake. Our unique combination of different technologies will lead to the identification of viral and cellular interaction partners which will in parallel be specifically targeted by high-throughput compound screening to identify small molecules that inhibit virus-receptor interaction. Moreover, we will use our gained knowledge of tissue-specific post-translational modifications to develop improved vaccine candidates as additional prophylactic countermeasures against MARV. Our project will further deliver a blueprint experimental pipeline for the streamlined identification and antiviral targeting of proteins involved in the virus attachment process, a critical cornerstone of pandemic preparedness.
Funded Companies:
| Company name | Funding amount |
| EURICE EUROPEAN RESEARCH AND PROJECT OFFICE GmbH | €749,375 |
| HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GmbH | €2,042,411 |
| Institutul de Biochimie | €775,469 |
| Karolinska Institutet | €830,580 |
| PHILIPPS UNIVERSITAET MARBURG | €1,051,250 |
| Universitetet I Oslo | €907,209 |
| VIB VZW | €928,750 |
Source: https://cordis.europa.eu/project/id/101191739
The filing refers to a past date, and does not necessarily reflect the current state.
The visualizations for "EURICE EUROPEAN RESEARCH AND PROJECT OFFICE GmbH - EU funding (€7,285,044): Comparative signature of Marburg virus cell activation as a blueprint for the identification of antiviral targets against newly emerging viruses"
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
